Track Arvinas, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Arvinas, Inc. ARVN · Stock Open Arvinas, Inc. in new tab

6.82 USD
P/E
30.23
EPS
-0.08
P/B
0.87
ROE
-1.76
Beta
1.80
Target Price
14.00 USD
Arvinas, Inc. logo

Arvinas, Inc.

🧾 Earnings Recap – Q1 2026

Arvinas shares ticked up modestly by 2.2% following approval and licensing of VEPPANU but the market’s tepid response suggests investors remain cautious about near-term commercial execution and longer-term pipeline visibility.

  • The FDA approved VEPPANU, the first PROTAC degrader approved for ESR1-mutant, ER+/HER2- advanced breast cancer, marking a milestone for Arvinas’ platform.
  • Arvinas licensed global commercialization, development, and manufacturing rights for VEPPANU to Rigel Pharmaceuticals, opting to focus internal resources on pipeline innovation.
  • Phase 1 data for ARV-102 in Parkinson’s disease demonstrated approximately 50% reductions in cerebrospinal fluid LRRK2 at day 14 sustained through day 28, alongside dose-dependent biomarker improvements with good tolerability.
  • The company maintains four ongoing Phase 1 clinical programs and a disciplined capital allocation approach but provided limited detail on near-term milestones or revenue guidance from VEPPANU.
  • The modest stock movement implies investor reservations on commercial visibility and execution risks despite scientific validation and platform progress.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
P/E30.23
EPS-0.08
Book Value7.84
Price to Book0.87
Debt/Equity1.44
% Insiders8.682%
Growth
Revenue Growth-0.99%
Estimates
Forward P/E-2.15
Forward EPS-3.18
Target Mean Price14.00

DCF valuation

Model fair value for Arvinas, Inc. (ARVN)
Result
Sign in to run the valuation for ARVN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Buy · mean target 14.00 USD (low 8.00, high 21.00) · as of 14 Nov 2026
Low 8.00
Mean 14.00
High 21.00
Price 6.82
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Arvinas, Inc. Logo Arvinas, Inc. Analysis (ARVN)

United States Health Care Official Website Stock

Is Arvinas, Inc. a good investment? Arvinas, Inc. (ARVN) is currently trading at 6.82 USD. Market analysts have a consensus price target of 14.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 30.23. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Arvinas, Inc. is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is -3.18.

Investor FAQ

Does Arvinas, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Arvinas, Inc.?

Arvinas, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -0.08.

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Exchange Ticker
NMS (United States) ARVN
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion